Key Takeaways
Abbott Laboratories' fiscal year 2025 (calendar year ended December 31, 2025) demonstrated the operational durability of one of the most diversified large-cap healthcare companies through a year of normalized post-COVID demand patterns and continued growth in the strategically positioned diabetes care, structural heart, and adult nutrition franchises: revenue of approximately $42-43.5B (+5-7% YoY excluding COVID-related test sales decline; reported revenue growth approximately +4-5% reflecting the multi-year wind-down of FY2020-FY2022 COVID test revenue), adjusted operating margin of approximately 22% generating operating income of approximately $9.5B, and adjusted EPS of approximately $5.15-5.30 on approximately 1.74B diluted shares. The structural identity that distinguishes Abbott from peer healthcare companies (Johnson & Johnson focused on pharma + medtech, Medtronic focused on devices, Becton Dickinson focused on medical technology) is the four-segment diversification across Medical Devices, Diagnostics, Established Pharmaceuticals (international branded generics), and Nutrition (Similac infant formula plus Ensure adult nutrition) — a portfolio that provides revenue stability through individual segment cycles and a dividend aristocracy (53 consecutive annual dividend increases) that few healthcare companies can match. The investment thesis for Abbott in FY2026 centers on three structural questions: (1) whether the FreeStyle Libre continuous glucose monitor (CGM) franchise — generating approximately $7B+ in FY2025 revenue and growing approximately 18-22% annually as CGM adoption expands beyond the Type 1 diabetes user base into Type 2 diabetes plus the recently FDA-cleared "Lingo" consumer wellness/biowearable category — sustains its category leadership against Dexcom's G7/G8 platform; (2) whether the Diagnostics segment, which has been compressing on COVID test revenue wind-down (from peak FY2021 COVID revenue of approximately $7B to approximately $1B FY2025), stabilizes and resumes core lab + rapid diagnostic + molecular diagnostic growth; and (3) whether the Nutrition segment continues recovering from the FY2022 Similac infant formula contamination crisis (Cronobacter sakazakii contamination at the Sturgis Michigan plant that triggered a major US infant formula shortage) toward pre-crisis market share and growth rates.
Abbott Laboratories was founded in 1888 in Chicago by Wallace Calvin Abbott — a homeopathic physician — to manufacture standardized medication doses (an innovation in pharmaceutical manufacturing at the time). The 137-year operational history transformed Abbott into the diversified healthcare company it is today, with strategic milestones including the introduction of branded pharmaceuticals (Norvir HIV antiretroviral, Humira anti-TNF biologic eventually spun off into AbbVie in 2013), the development of cardiovascular medical devices (acquired through Knoll Pharma 2001 and St. Jude Medical 2017 for $25B), and the diabetes care franchise (FreeStyle blood glucose meters, FreeStyle Libre CGM platform launched 2014). CEO Robert Ford, who has led Abbott since March 2020 (succeeding Miles White), has overseen the COVID test revenue wind-down navigation, the post-Similac crisis recovery, the continued expansion of FreeStyle Libre into Type 2 diabetes, and the operational discipline that has maintained Abbott's industry-leading dividend track record. The strategic identity that distinguishes Abbott's contemporary positioning from peer healthcare companies is the deliberate emphasis on durable-growth franchises (diabetes care, structural heart, electrophysiology) rather than the high-volume-but-cyclical orthopedics or commodity diagnostics that have compressed peer companies' growth profiles.
Business Structure
Abbott reports through four primary business segments aligned with end-market and product technology categories.
Medical Devices (~$19B revenue, ~45% of total): The largest and fastest-growing segment, including:
- Diabetes Care (~$7B revenue, +18-22% growth): FreeStyle Libre 2/3 continuous glucose monitor — the world's leading CGM by user count (approximately 6M+ users globally) targeting both diabetes (Type 1, Type 2 on insulin therapy, increasingly Type 2 not on insulin) and consumer wellness (Lingo biowearable for general population glucose tracking).
- Cardiovascular (~$8B revenue): Structural heart (MitraClip mitral valve repair, the leading transcatheter mitral repair device with approximately 50%+ global market share; TriClip tricuspid repair; Amplatzer cardiac plugs and occluders), heart failure (HeartMate left ventricular assist devices), electrophysiology (cardiac mapping and ablation catheters competing with Boston Scientific and Johnson & Johnson Biosense Webster), vascular (drug-eluting stents, pacemakers).
- Neuromodulation (~$1B revenue): Spinal cord stimulators for chronic pain management.
- Diagnostics-related (~$3B revenue, included in Medical Devices for some reporting purposes): Point-of-care testing.
Diagnostics (~$10B revenue, ~24% of total): Core laboratory diagnostics (Alinity automated lab platform), rapid diagnostics (BinaxNOW respiratory tests, Panbio infectious disease), molecular diagnostics, blood transfusion screening. The segment compressed materially as COVID-related test revenue wound down — peak COVID diagnostics revenue of approximately $7B in FY2021 declined to approximately $1B in FY2025 (representing residual respiratory infection testing and selected ongoing surveillance).
Established Pharmaceuticals (EPD) (~$5.5B revenue, ~13% of total): International branded generic pharmaceuticals — Abbott's strategically distinctive positioning in branded generics (off-patent pharmaceuticals sold under Abbott brand names in international markets, predominantly emerging markets where branded generics command meaningful pricing premiums versus pure unbranded generics). Key markets: India, Russia, Latin America, Middle East/Africa. Categories: gastrointestinal, cardiovascular, women's health, pediatric, central nervous system. The segment generates higher operating margins than expected for a generics-related business (~20-22%) reflecting the brand premium structure.
Nutrition (~$8.5B revenue, ~20% of total): Adult nutrition (Ensure ready-to-drink protein supplements, Glucerna for diabetes, Pedialyte oral electrolyte solutions) plus infant formula (Similac brand — the second-largest US infant formula brand after Mead Johnson Enfamil, growing globally). Adult nutrition has been a consistent organic growth contributor (4-7% growth on aging US population demographics and protein supplementation expansion). Infant formula has been recovering from the FY2022 Sturgis Cronobacter contamination crisis through FY2024-FY2025 — recapturing market share lost during the recall period and the FDA Sturgis plant shutdown.
Key Core Metrics Performance
Revenue, Margin, and EPS Trajectory (FY2021–FY2025)
| Fiscal Year | Revenue (Reported) | Organic Sales Growth (Ex-COVID) | Adj. Op. Margin | Adj. EPS |
|---|---|---|---|---|
| FY2021 | ~$43.1B | +13% | ~24.0% | ~$5.24 |
| FY2022 | ~$43.7B | +6% (COVID test revenue still elevated) | ~22.5% | ~$5.34 |
| FY2023 | ~$40.1B | +9% (excluding COVID test wind-down) | ~22.0% | ~$4.44 |
| FY2024 | ~$42.0B | +9% (excluding COVID test wind-down) | ~22.5% | ~$4.67 |
| FY2025 | ~$43B | +7-8% (essentially no COVID test impact remaining) | ~22.5% | ~$5.20 |
The pattern of reported revenue declining FY2022 → FY2023 reflects the COVID test revenue wind-down (from approximately $7B FY2021 peak to approximately $1B FY2025), masking the underlying strong organic growth in core franchises. The adjusted operating margin maintaining approximately 22-22.5% through this transition reflects operational discipline and favorable mix shift toward Medical Devices (higher-margin segment growing faster than Diagnostics).
Segment Operating Income Mix (FY2025)
| Segment | Revenue | Adj. Operating Margin | Adj. Operating Income |
|---|---|---|---|
| Medical Devices | ~$19B | ~30% | ~$5.7B |
| Diagnostics | ~$10B | ~14% | ~$1.4B |
| Established Pharmaceuticals | ~$5.5B | ~21% | ~$1.15B |
| Nutrition | ~$8.5B | ~17% | ~$1.45B |
| Corporate/Other | — | — | -$0.20B |
| Total | ~$43B | ~22.5% | ~$9.5B |
Medical Devices' approximately 30% operating margin and approximately 60% of consolidated operating income on approximately 45% of revenue makes it both the largest segment and the most strategically important for Abbott's earnings power.
FreeStyle Libre Trajectory
| Fiscal Year | Libre Revenue | Global Users (M) | Growth |
|---|---|---|---|
| FY2021 | ~$3.7B | ~3.5 | +35% |
| FY2022 | ~$4.6B | ~4.5 | +24% |
| FY2023 | ~$5.6B | ~5.5 | +22% |
| FY2024 | ~$6.5B | ~6.0 | +18% |
| FY2025 | ~$7.5B | ~6.5+ | +18-22% |
The FreeStyle Libre franchise growth — from approximately $3.7B in FY2021 to approximately $7.5B in FY2025 — represents the most important single growth driver for Abbott, supported by category expansion (CGM adoption among Type 2 diabetes patients on insulin, increasingly Type 2 not on insulin), geographic expansion (international market penetration), and product evolution (Libre 2 in 2020, Libre 3 in 2022 with smaller form factor and direct smartphone connectivity, Libre 3+ in 2024, Lingo consumer wellness biowearable in 2024).
Market Evaluation
Abbott trades at approximately 23-27x forward adjusted EPS — premium healthcare multiples that reflect both the dividend aristocrat status and the FreeStyle Libre growth contribution to the consolidated profile. The bull case is sustained Libre franchise growth + Diagnostics stabilization + Nutrition full recovery: if Libre revenue grows toward approximately $11-12B by FY2027 (continued user growth plus pricing plus Lingo consumer wellness expansion), if Diagnostics returns to mid-single-digit organic growth as COVID test revenue normalizes fully and core lab + molecular diagnostic growth accelerates, and if Nutrition continues recovering toward pre-Sturgis infant formula market share, total revenue could approach $48-50B with adj. EPS reaching $6.20-6.60 by FY2027 — supporting equity at sustained 23-25x and continued dividend growth toward $2.50+ per share. The bear case is Libre competitive intensity + Nutrition slow recovery: if Dexcom's G8 platform (launching FY2026 with extended wear time and improved accuracy claims) captures meaningful share at Type 2 diabetes patient acquisition events, if Senseonics implantable CGM gains traction at long-wear-time tier, or if Similac market share recovery stalls below pre-Sturgis levels, EPS growth could remain in mid-single-digits with limited multiple expansion runway.
FreeStyle Libre and the CGM Category Expansion Strategy
The structural opportunity that defines Abbott's growth thesis is the continuous glucose monitor category expansion — the strategic insight that CGM technology, originally developed for Type 1 diabetes management, has progressively addressable patient populations including Type 2 diabetes on insulin (highly relevant for blood sugar control), Type 2 diabetes not on insulin (emerging clinical benefit), pre-diabetes, and ultimately consumer wellness applications (general health monitoring among non-diabetic populations interested in metabolic health). Each expansion of the addressable market multiplies the CGM category TAM, and Abbott's FreeStyle Libre is positioned to capture meaningful share at each successive expansion tier.
The Type 2 diabetes opportunity is the largest near-term growth driver: approximately 36M US adults have diagnosed Type 2 diabetes plus approximately 95M with prediabetes, of whom approximately 8-10M are currently using CGM (vs. approximately 3M Type 1 patients, where CGM adoption is much higher penetration). Abbott's Libre 3 product positioning at lower price points than Dexcom G7 ($75-90/sensor for Libre 3 vs. $90-110/sensor for Dexcom G7 in commercial pricing) supports broader Type 2 patient penetration, and Medicare reimbursement coverage expansion for CGM in Type 2 diabetes (effective FY2023 onward for insulin-treated Type 2; expanded for non-insulin Type 2 in selected markets) supports the addressable market expansion.
The Lingo consumer wellness opportunity is the most novel: FDA cleared Lingo (Abbott's biowearable platform that uses the FreeStyle Libre sensor technology applied to consumer wellness applications) for over-the-counter consumer use in mid-2024. Lingo addresses non-diabetic consumers interested in metabolic health insights — tracking glucose responses to meals, exercise, stress, and sleep. The category is novel and the consumer pricing economics are still being established, but the opportunity is large: if even 1-2% of the approximately 250M US adult non-diabetic population adopts wellness CGM at $200-400 annual program economics, the addressable revenue is $5-10B annually for the leading wellness CGM provider. Abbott's first-mover advantage with Lingo (Dexcom's competing Stelo wellness CGM launched simultaneously, but Abbott's Libre brand recognition supports a stronger consumer launch) positions Lingo as a meaningful FY2026-FY2027 growth contributor if consumer adoption materializes.